Preservation of hair during chemotherapy. Also known as the “Jessica Huffman Bill”
Summary
HB 4089, known as the “Jessica Huffman Bill,” addresses preservation of hair for patients undergoing chemotherapy. Based on the bill caption and legislative context, the measure is intended to support cancer patients by allowing or encouraging access to hair-preservation-related care during chemotherapy treatment. The bill became effective ninety days after passage on June 8, 2026.
Although the full statutory text was not available in the provided materials, the bill’s subject suggests it likely creates or modifies state law to recognize hair-preservation treatment as part of cancer care, potentially affecting insurers, healthcare providers, and patients receiving chemotherapy. Its practical effect would be to expand treatment options or protections for individuals facing chemotherapy-related hair loss, and it may require coordination among medical professionals and payers to implement any new coverage or procedural requirements.
Impact
HB 4089 likely affects state health and insurance law by establishing a new policy framework for hair preservation during chemotherapy, with implications for cancer treatment providers, patients, and possibly health benefit plans. Depending on the enacted language, it may require coverage, disclosure, referral, or access standards related to scalp cooling or similar hair-preservation methods. The bill’s enactment means any affected statutes or administrative rules must now be read in light of this new patient-centered cancer care provision.
Sentiment
The available voting history indicates strong bipartisan support and little opposition. The bill passed the House 95-0 and the Senate 31-1, suggesting broad agreement that the measure addresses a sympathetic healthcare issue and provides meaningful support to cancer patients. No committee debate transcript was provided, but the near-unanimous votes indicate generally favorable sentiment around the bill.
Contention
No specific points of contention are documented in the provided materials. The only visible sign of disagreement is a single dissenting vote in the Senate, but no explanation is available for that vote. If there was debate, it likely would have centered on implementation details such as insurance coverage, cost, medical necessity, or the scope of any mandated access to hair-preservation treatment, but those issues are not confirmed in the record provided.
Prohibiting chairmen of state political parties during or up to one year after the termination of their employment as chairmen of those political parties from registering as lobbyists